Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.39 |
| ▸ | AURKA | O14965 | 2/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5720872 | 0.83 | GRM5 (0.46) | GRM5AURKACCNA2CDK2CCNA1 | |
| SCHEMBL5720863 | 0.80 | CCNA2 (0.46) | GRM5AURKACCNA2CDK2CCNA1 | |
| SCHEMBL5720811 | 0.79 | ADORA3 (0.42) | AURKACCNA2CDK2CCNA1CYP3A4 | |
| SCHEMBL5720832 | 0.77 | AURKA (0.40) | AURKACCNA2CDK2CCNA1CYP3A4 | |
| SCHEMBL5720843 | 0.73 | CYP3A4 (0.40) | AURKACCNA2CDK2CCNA1CYP3A4 | |
| SCHEMBL5720841 | 0.72 | ACACB (0.43) | SMN1; SMN2NPC1RAB9A | |
| SCHEMBL5720815 | 0.70 | BRD4 (0.55) | AURKACCNA2CDK2CCNA1 | |
| SCHEMBL5720813 | 0.69 | CDK2 (0.38) | AURKACCNA2CDK2CCNA1CYP3A4 | |
| SCHEMBL5720894 | 0.69 | TSHR (0.43) | AURKACCNA2CDK2CCNA1CYP3A4 | |
| SCHEMBL2924461 | 0.68 | CCNA2 (0.37) | GRM5AURKACCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135508-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2006-06-22 | — | — | US | disclosed |
| EP-1527074-A1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Pharmacia Italia S.p.A. (IT) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004013144-A1 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA SPA (IT) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135508-A1 | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K15, MAP3K5, MAP3K19 | GRM5 1398/4885AURKA 173/4885CCNA2 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.